Effects of Rituximab Combined with Cyclophosphamide and Prednisone on Renal Function and Serum Level of Anti-M-Type Phospholipase A2 Receptor Antibody in Patients with Idiopathic Membranous Nephropathy
Objective:To investigate the effects of rituximab combined with cyclophosphamide and prednisone on renal function and serum level of anti-M-type phospholipase A2 receptor(PLA2R)antibody in patients with idiopathic membranous nephropathy(IMN).Methods:A total of 64 IMN patients treated in a hospital from June 2020 to December 2022 were selected and assigned to the control group and observation group by random number table method,with 32 patients in each group.All patients were treated with conventional treatment such as blood pressure control,lipid regulation and anticoagulation,the control group was given prednisone acetate tablets and cyclophosphamide for injection in addition to the conventional treatment,and the observation group was treated with rituximab injection in addition to the treatment given in the control group.Serum level of albumin,blood lipid parameters[total cholesterol(TC)and triglyceride(TG)],serum level of anti-PLA2R antibody,renal function indices[serum creatinine(Scr),blood urea nitrogen(BUN)],24h urinary protein quantification(24hpro)and adverse reactions were compared between the two groups.Results:After treatment,the serum level of albumin were increased in both groups(P<0.05),and was higher in the observation group than that in the control group(P<0.05).TC and TG levels were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The serum level of anti-PLA2R antibody was decreased in both groups(P<0.05),and was lower in the observation group than that in the control group(P<0.05).The levels of Scr and BUN were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The 24hpro was decreased in both groups(P<0.05),and was lower in the observation group than that in the control group(P<0.05).No statistically significant difference in the incidence of adverse reactions was observed between the two groups(P>0.05).Conclusion:Rituximab combined with cyclophosphamide and prednisone can increase serum albumin level,regulate levels of serum anti-PLA2R antibody and blood lipids,improve renal function,and does not increase the risk of adverse reactions.
国家科技期刊平台
NSTL
万方数据
